<ul data-eligibleForWebStory="false"><li>Glenmark Pharmaceuticals' unit has signed an exclusive licensing pact with AbbVie to globally manufacture ISB 2001, a cancer drug used in cancer treatment.</li><li>Under the agreement, IGI Therapeutics SA, linked to Glenmark's innovation arm, will collaborate with AbbVie to develop, manufacture, and commercialize ISB 2001 in various regions.</li><li>ISB 2001, a trispecific T-cell engager developed using IGI's BEAT protein platform, targets difficult-to-treat cancers and offers a treatment option for patients.</li><li>The partnership aims to provide complementary access pathways for ISB 2001, leveraging AbbVie's reach in major markets and Glenmark's commercial strength in emerging markets to expand access to innovative cancer treatments.</li></ul>

Glenmark Unit Signs Exclusive Licensing Pact With AbbVie For Cancer Drug

Discover more